Ozaras Resat, Tahan Veysel, Mert Ali, Uraz Suleyman, Kanat Mustafa, Tabak Fehmi, Avsar Erol, Ozbay Gulsen, Celikel Cigdem Ataizi, Tozun Nurdan, Senturk Hakan
Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
J Clin Gastroenterol. 2004 May-Jun;38(5):449-52. doi: 10.1097/00004836-200405000-00011.
Hepatic granulomas are not usual findings in chronic hepatitis C. A few studies addressing the frequency of hepatic granulomas in chronic hepatitis C reported it as less than 10%. The presence of it has been suggested to predict a favorable response to interferon treatment. Also, case reports described the development of hepatic granulomas after interferon treatment. In this study, we aimed to detect the prevalence of hepatic granulomas in chronic hepatitis C and to identify the causes other than chronic hepatitis C, if present, to search whether there is an association between the presence of granuloma and response to interferon treatment and also to see whether interferon leads to the formation of hepatic granulomas.
Patients from 3 university clinics were included. All patients with chronic hepatitis C were determined. All patients with hepatic granulomas were screened for the other causes of hepatic granuloma with tuberculin skin test, chest X-ray and computed tomography, Venereal Disease Research Laboratory, and Brucella agglutination tests. The histologic assessment of liver biopsies was done by the same pathologist in each center.
A total of 725 liver biopsies of 605 patients with chronic hepatitis C were screened. In 8 patients, hepatic granulomas were detected in the initial liver biopsies. Four patients had repeat biopsies, and all had hepatic granulomas again. The prevalence of hepatic granulomas in patients with chronic hepatitis C was calculated as 1.3% (8 of 605) in reference to patient population. Presence or absence of hepatic granulomas was seemingly stable. All patients with hepatic granulomas had negative results of tuberculin skin test, Venereal Disease Research Laboratory, chest X-ray and computed tomography, and Brucella agglutination tests. All repeat biopsies were obtained after interferon (+/- ribavirin) in varying doses and duration. Four of 8 patients with hepatic granulomas were found to respond interferon therapy. No patient was found to develop hepatic granulomas after interferon therapy.
Hepatic granulomas are a rare finding in HCV infection. The presence of it does not seem to predict the response to interferon therapy. The development of hepatic granulomas during interferon therapy is not usual.
肝肉芽肿在慢性丙型肝炎中并非常见表现。少数关于慢性丙型肝炎中肝肉芽肿发生率的研究报告其发生率低于10%。有人提出肝肉芽肿的存在可预测对干扰素治疗的良好反应。此外,病例报告描述了干扰素治疗后肝肉芽肿的发生。在本研究中,我们旨在检测慢性丙型肝炎中肝肉芽肿的患病率,确定除慢性丙型肝炎外的其他病因(若存在),探究肉芽肿的存在与干扰素治疗反应之间是否存在关联,以及观察干扰素是否会导致肝肉芽肿的形成。
纳入来自3所大学诊所的患者。确定所有慢性丙型肝炎患者。对所有肝肉芽肿患者进行结核菌素皮肤试验、胸部X线和计算机断层扫描、性病研究实验室检查以及布鲁氏菌凝集试验,以筛查肝肉芽肿的其他病因。每个中心由同一位病理学家对肝活检进行组织学评估。
共筛查了605例慢性丙型肝炎患者的725份肝活检标本。在8例患者的初次肝活检中检测到肝肉芽肿。4例患者进行了重复活检,且再次活检均发现有肝肉芽肿。以患者总数计算,慢性丙型肝炎患者中肝肉芽肿的患病率为1.3%(605例中的8例)。肝肉芽肿的有无似乎较为稳定。所有肝肉芽肿患者的结核菌素皮肤试验、性病研究实验室检查、胸部X线和计算机断层扫描以及布鲁氏菌凝集试验结果均为阴性。所有重复活检均在接受不同剂量和疗程的干扰素(±利巴韦林)治疗后进行。8例肝肉芽肿患者中有4例对干扰素治疗有反应。未发现患者在干扰素治疗后出现肝肉芽肿。
肝肉芽肿在丙型肝炎病毒感染中是一种罕见表现。其存在似乎不能预测对干扰素治疗的反应。干扰素治疗期间肝肉芽肿的发生并不常见。